Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -10.66%6 EV-to-EBITDA is -3.12 as of Aug. 01, 2026. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 411 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Veraxa Biotech Holding AG's enterprise value is $250.95 Mil.
Veraxa Biotech Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-80.55 Mil. Therefore, Veraxa Biotech Holding AG's EV-to-EBITDA for today is -3.12.
The historical rank and industry rank for Veraxa Biotech Holding AG's EV-to-EBITDA or its related term are showing as below:
VRXA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.12 Med: 0 Max: 0
Current: -3.12
VRXA's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs VRXA: -3.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Veraxa Biotech Holding AG (NAS:VRXA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veraxa Biotech Holding AG's PE Ratio (TTM) for today is calculated as:
Veraxa Biotech Holding AG's share price for today is $1.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veraxa Biotech Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.584.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG EV-to-EBITDA Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
0.00
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-EBITDA
0.00
0.00
0.00
0.00
0.00
VRXA vs TTRX, IRD, IFRX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's EV-to-EBITDA falls into.
Veraxa Biotech Holding AG's current Enterprise Value is $250.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veraxa Biotech Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-80.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a EV-to-EBITDA of -3.12 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Veraxa Biotech Holding AG. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 411 companies in the Biotechnology industry.
Is Veraxa Biotech Holding AG's EV-to-EBITDA too high?
Veraxa Biotech Holding AG's current EV-to-EBITDA is -3.12. Based on the distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's EV-to-EBITDA compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 411 companies for EV-to-EBITDA. This places Veraxa Biotech Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Veraxa Biotech Holding AG. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current EV-to-EBITDA is -3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current EV-to-EBITDA of -3.12. The current EV-to-EBITDA is -3.12. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current EV-to-EBITDA is -3.12 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
